[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  30.00 4.41% 710.00 680.00 740.00 710.00 710.00 710.00 280,744 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -10.6 -16.0 - 513

Renalytix Says U.S. Plans to Scrap Medicare Coverage Program Won't Affect Plans

14/09/2021 7:12pm

Dow Jones News


Renalytix (LSE:RENX)
Historical Stock Chart


From Aug 2021 to Sep 2021

Click Here for more Renalytix Charts.

By Joe Hoppe

 

Renalytix PLC said Tuesday that plans to scrap a coverage pathway for Medicare beneficiaries to access FDA-cleared or approved breakthrough devices in the U.S. won't likely materially affect business plans for its technology.

The diagnostics group said that following a previously disclosed delay to implementing the final rule establishing the Medicare Coverage of Innovative Technology, or MCIT pathway, the final rule has been proposed to be repealed before Dec. 15.

The Centers for Medicare and Medicaid Services said that it believes there were other ways to provide innovation and access to important new technologies.

The company said on March 15 that the MCIT rule, based on an executive order issued in October 2019, will provide four-year national Medicare coverage for technologies that the Food and Drug Administration recognizes as breakthrough devices, accelerating their rollout. The company's lead product, KidneyIntelX, was granted FDA breakthrough designation in May 2019 and submitted its final FDA application in August 2020.

"Given our trajectory for accumulating real-world utility evidence, however, we do not believe there will be a material impact on the KidneyIntelX business plan and are confident of continuing success to secure comprehensive government and private insurance reimbursement for KidneyIntelX," Chief Executive James McCullough said.

 

Write to Joe Hoppe at joseph.hoppe@wsj.com

 

(END) Dow Jones Newswires

September 14, 2021 13:57 ET (17:57 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Renalytix Chart

1 Year Renalytix Chart

1 Month Renalytix Chart

1 Month Renalytix Chart
ADVFN Advertorial
Your Recent History
LSE
RENX
Renalytix
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210927 17:37:10